Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / ALXN - Alexion's ravulizumab successful in late-stage aHUS study; shares up 2% premarket

ALXN - Alexion's ravulizumab successful in late-stage aHUS study; shares up 2% premarket

Alexion Pharmaceuticals Inc.
  • A Phase 3 clinical trial evaluating Alexion Pharmaceuticals' (NASDAQ:ALXN) ULTOMIRIS (ravulizumab-cwvz) (formerly ALXN1210) in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome (aHUS) met the primary endpoint of complete thrombotic microangiopathy (TMA) response (defined as hematologic normalization and improved kidney function).
  • More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,
    • Read more ...
Stock Information
Company Name: Alexion Pharmaceuticals Inc.
Stock Symbol: ALXN
Market: NASDAQ
Website: alexion.com
Menu
ALXN ALXN Quote ALXN Short ALXN News ALXN Articles ALXN Message Board
Get ALXN Alerts

News, Short Squeeze, Breakout and More Instantly...